Fast-dissolving galanthamine hydrobromide tablet

Details Fast-dissolving galanthamine hydrobromide tablet Fast-dissolving galanthamine hydrobromide tablet

1998-12-09

2000-08-08

Spear, James M.

Drug, bio-affecting and body treating compositions

Preparations characterized by special physical form

Tablets, lozenges, or pills

424465, 424474, 424480, 424482, 514770, 5147723, 514777, 514781, 514960, A61K 930

Patent

active

060998636

DESCRIPTION:

BRIEF SUMMARY
CROSS REFRERENCE TO RELATED APPLICATIONS

This application is a National Stage application under 35 U.S.C. .sctn.371 of PCT/EP97/02986 led Jun. 6, 1997, which claims priority from EP 96.201. 676.2, filed Jun. 14, 1996.
The present invention is concerned with a fast-dissolving tablet for oral administration comprising as an active ingredient a therapeutically effective amount of galanthamine hydrobromide (1:1) and a pharmaceutically acceptable carrier, characterized in that said carrier comprises a spray-dried mixture of lactose monohydrate and microcrystalline cellulose (75:25) as a diluent, and a disintegrant; and with a direct compression process of preparing such fast-dissolving tablets.
Galanthamine, a tertiary alkaloid, has been isolated from the bulbs of the Caucasian snowdrops Galantanus woronowi (Proskurnina, N. F. and Yakoleva, A. P. 1952, Alkaloids of Galanthus woronowi, II. Isolation of a new alkaloid. (In Russian.) Zh. Obschchei Khim. (J. Gen. Chem.) 22, 1899-1902). It has also been isolated from the common snowdrop Galanthus nivalis (Boit, 1954). The chemical name of galanthamine is [4aS-(4a.alpha., 6.beta., 8aR*)]-4a, 5, 9, 10, 11, 12-hexahydro-3-methoxy- 11-methyl-6H-benzofuro[3a, 3, 2-ef][2]benzazepin-6-ol; both the base compound and its hydrobromide are laevorotatory. Galanthamine is a well-known acetylcholinesterase inhibitor which is active at nicotinic receptor sites but not on muscarinic receptor sites. It is capable of passing the blood-brain barrier in humans, and presents no severe side effects in therapeutically effective dosages.
Galanthamine has been used extensively as a curare reversal agent in anesthetic practice in Eastern bloc countries (cf. review by Paskow, 1986) and also experimentally in the West (cf. Bretagne and Valetta, 1965: Wislicki, 1967; Consanitis, 1971).
Galanthamine has been marketed by the Waldheim (Sanochemia Gruppe) as Nivalin.TM. in Germany and Austria since the 1970s for indications such as facial neuralgia.
The use of galanthamine or an analogue or a pharmaceutically acceptable acid addition salt thereof for the preparation of a medicament for treating Alzheimer's Dementia (AD) and related dementias has been described in EP-0,236,684 (U.S. Pat. No. 4,663,318). This patent only has a generic disclosure of possible dosage forms of galanthamine.
The use of galanthamine for treating alcoholism and the administration via a transdermal transport system (TTS) or patch is disclosed in EP-0,449,247. Similarly, the use of galanthamine in the treatment of nicotine dependence using administration via a transdermal transport system (TTS) or patch is disclosed in WO-94/16708.
A number of applications by E. Snorrason disclose the use of galanthamine, analogues thereof and pharmaceutically acceptable salts thereof for the preparation of medicaments for treating mania (U.S. Pat. No. 5,336,675), chronic fatigue syndrome (CFS) (EP-0,515,302 ; U.S. Pat. No. 5,312,817), and the negative effects of benzodiazepine treatment (EP-0,515,301). In these applications and patents, e.g. in U.S. Pat. No. 5,312,817, a number of specific tablet formulations of galanthamine hydrobromide are given. In particular, these formulations are as follows:
Composition of 1 tablet (60 mg) containing 1mg galanthamine hydrobromide


______________________________________ Galanthamine hydrobromide 0.001 g Calcium phosphate 0.032 g Lactose 0.005 g Wheat Starch 0.0056 g Microcrystalline Cellulose 0.015 g Talc 0.0007 g Magnesium Stearate 0.0007 g ______________________________________
Composition of 1 tablet (80 mg) containing 5 mg galanthamine hydrobromide; film-coat composition unknown [Nivalin.TM., Waldheim, Ltd, Vienna, Austria] (F 3)


______________________________________ Galanthamine hydrobromide 0.005 g Calcium phosphate 0.024 g Lactose 0.004 g Wheat Starch 0.004 g Microcrystalline Cellulose 0.04 g Talc 0.002 g Magnesium Stearate 0.001 g ______________________________________
Composition of 1 tablet (120 mg) containing 10 mg galanthamine

REFERENCES:
patent: 4693750 (1987-09-01), Bauer et al.
patent: 5633238 (1997-05-01), Snorrason

Affiliated with

Also associated with

Rating

Fast-dissolving galanthamine hydrobromide tablet does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Fast-dissolving galanthamine hydrobromide tablet, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fast-dissolving galanthamine hydrobromide tablet will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1147829